236 Evaluation of Sexual Function after Dutasteride Treatment in Patients with Once Negative Prostate Biopsy and Benign Prostate Hyperplasia. (1st May 2022) - Taniguchi, H
ABSTRACT: Introduction: 5α-reduced inhibitors (5ARIs) are usually administered to patients with benign prostatic hyperplasia, however, whether 5ARIs affect sexual function remains a controversial issue for both patients and urologists. Objective: In this study, we evaluated the impact of dutasteride treatment for erectile function in patients with once-negative prostate biopsy and benign prostate hyperplasia. Methods: 81 patients with benign prostate hyperplasia were enrolled in a one-arm prospective study. They were administrated 0.5 mg/day of dutasteride for 12 months. Patient characteristics, change of IPSS and IIEF-15 scores at baseline and 12 months after dutasteride administration were examined. Results: The mean ± SD age of the patients was 69.4 ± 4.9 years and the prostate volume was 56.6 ± 21.3 mL, respectively. The mean ± SD prostate volume and PSA levels were decreased 25.0% and 50.9%, respectively, after 12 months of dutasteride administration. IPSS total, voiding subscore, storage subscore, and QOL score significantly improved after 12 months of dutasteride administration. No significant change was observed in any of the IIEF scores after 12 months. There was no decrease in EF severity. Conclusion: Twelve months administration of dutasteride for patients with BPH improved urinary function and did not increase the risk of sexual dysfunction. Disclosure: Work supported by industry: no.